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Dietary carbohydrate content  
and glycaemic control in type 2  
diabetes patients treated  
with pre-mixed human insulins
Podaż węglowodanów w diecie i kontrola glikemii u pacjentów  
leczonych za pomocą mieszanek insuliny ludzkiej
ABSTRACT
Introduction. The treatment with pre-mixed human 
insulins (PMHI) is globally one of the most popular 
models of insulin therapy. Achieving good glycaemic 
control on PMHI may, however, be difficult, mostly due 
to inconsistent calorie and carbohydrate intake. The 
aim of the study was to examine the impact of dietary 
modification on glucose levels in patients with type 2 
diabetes mellitus (T2DM) treated with PMHI. 
Materials and methods. In this prospective cross-over 
analysis we studied 8 T2DM PMHI treated individuals 
(mean HbA1c 8.4%). We exposed patients to 2 diets, 
both based on steady calorie/carbohydrate content: 
„A” — 50% calories from carbohydrates, 30% from 
fat, 20% from protein, „B”— 40% from carbohydrates, 
30% from fat and 30% from protein. The study was 
performed in home settings, all the meals were de-
livered to the patients. Each patient was exposed to 
diet A for 9 days, than after 7 days of wash-out to 
9 days of diet B. Glucose patterns were assessed with 
continuous glucose monitoring system (CGMS, iPro, 
Medtronic, USA). 
Results. Switching from diet A to diet B resulted in 
a decrease in mean glucose levels (CGMS data) from 
145 mg/dL to 133 mg/dL (p = 0.0001), SD reduction 
from 51 to 42 mg/dL (p = 0.0429), and a decrease in 
time spent above the target of 180 mg/dL from 18% 
to 11% (p = 0.0006).
Conclusions. The study demonstrates that consistent 
and repeatable carbohydrate (CH) and calorie intake 
with moderate restriction of CHs helps to improve 
glycaemic control in this group of patients. (Diabet. 
Klin. 2015; 4, 4: 127–131)
Key words: type 2 diabetes, insulin, carbohydrates, 
glycaemic control, pre-mixed human insulins
STRESZCZENIE
Wstęp. Leczenie mieszankami insuliny ludzkiej (PMHI, 
pre-mixed human insulin) jest na całym świecie jednym 
z najpopularniejszych modeli insulinoterapii. Jednak 
osiągnięcie dobrej kontroli glikemii u osób stosujących 
PMHI może być trudne, głównie ze względu na zmien-
ne spożycie węglowodanów i podaż kalorii. Badanie 
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przeprowadzono w celu oceny wpływu modyfikacji 
diety na stężenia glukozy u chorych na cukrzycę typu 2 
(T2DM, type 2 diabetes mellitus) stosujących PMHI. 
Materiał i metody. Do tego prospektywnego badania 
przeprowadzonego w układzie naprzemiennym włą-
czono 8 chorych na T2DM leczonych PMHI (średnie stę-
żenie HbA1c 8,4%). U chorych zastosowano 2 diety, obie 
cechujące się stałą zawartością kalorii/węglowodanów: 
dieta A — 50% kalorii pochodzi z węglowodanów, 
30% — z tłuszczów, 20% — z białek; dieta B — 40% 
kalorii pochodzi z węglowodanów, 30% — z tłuszczów 
i 30% — z protein. Badanie prowadzono w warunkach 
domowych, dostarczano chorym wszystkie posiłki. Każ-
dy chory stosował dietę A przez 9 dni, a następnie po 
7-dniowym okresie wypłukiwania przez 9 dni stosował 
dietę B. Profile glukozy oceniano przy użyciu systemu 
ciągłego monitorowania glikemii (CGMS, continuous 
glucose monitoring system, iPro, Medtronic, USA).
Wyniki. Zmiana z diety A na dietę B spowodowała 
zmniejszenie średnich stężeń glukozy (dane z system 
CGMS) ze 145 mg/dl do 133 mg/dl (p = 0,0001), reduk-
cję SD z 51 do 42 mg/dl (p = 0,0429) oraz skrócenie 
czasu, w którym glikemia utrzymywała się powyżej pro-
gowej wartości 180 mg/dl z 18% do 11% (p = 0,0006).
Wnioski. W badaniu wykazano, że zapewnienie od-
powiedniej i powtarzalnej podaży węglowodanów 
i kalorii z umiarkowanym ograniczeniem węglowoda-
nów umożliwia poprawę kontroli glikemii u chorych 
na cukrzycę typu 2. (Diabet. Klin. 2015; 4, 4: 127–131)
Słowa kluczowe: cukrzyca typu 2, węglowodany, 
mieszanki insuliny ludzkiej
Introduction 
Achieving and maintaining good glycaemic control 
is a key objective in type 2 diabetes mellitus (T2DM) 
management. The progressive nature of the disease, 
related mainly to continuous deterioration of endog-
enous insulin secretion, requires a stepwise intensifi-
cation of the pharmacological treatment [1, 2]. Most 
T2DM patients will eventually need insulin therapy to 
maintain glycaemic control. In such a situation, pre-
mixed formulation is a common treatment option — in 
some countries almost half of the patients with T2DM 
diabetes use this model. Pre-mixed human insulins 
30 (PMHI 30), one of the popular premixed prepara-
tions, contains a fixed soluble human insulin compo-
nent, which makes 30% of the formulation, whereas 
Neutral Protamine Hagedorn (NPH) insulin constitutes 
the remaining 70%. When PMHI is injected before 
a meal, the former lowers postprandial glucose excur-
sions, while the latter provides basal insulin coverage. 
Treatment with premixed insulin is recommended 
by most clinical guidelines for T2DM patients as one 
of the options for initiation and intensification of 
insulin therapy [3]. However, many T2DM patients do 
not achieve recommended glycaemic goals even when 
treated with insulin [1]. This may be caused by a lack of 
detailed dietary recommendations for T2DM patients, 
which should be tailored to specific insulin therapy, 
for example PMHI injections. Since there is a general 
agreement that nutritional intervention is essential for 
diabetes management, defining an optimal dietary 
composition may be helpful in reaching therapeutic 
targets [4, 5]. Carbohydrates (CHs) are the most potent 
modifier of glycaemic patterns in patients with T2DM 
[4–9]. The aim of this study was to examine if repeat-
able CHs intake improves glycaemic control in T2DM 
patients treated with PMHI. 
Materials and methods 
Eight consecutive T2DM patients treated with PMHI 
who agreed to participate were enrolled. Their mean 
age was 68.9 years, mean T2DM duration — 9.8 years, 
mean body mass index — 28.48 kg/m2 and mean 
HbA1c — 8.4%. These patients were free from advanced 
microvascular complications. On the basis of clinical as-
sessment their pre-study compliance was satisfactory. 
Patients with severe hypoglycaemic episodes over the 
last 6 months before the study or with hypoglycaemia 
unawareness were excluded. All the study patients 
were treated with two injections of PMHI 30 with an 
average daily dose of 44.5 IU; in 7 cases insulin was 
combined with metformin (dose range 1000–2550 mg). 
The patients were exposed to two types diet, defined as 
A and B. Both diets were based on steady calorie and CH 
content: A — 50% calories from CH, 30% from fat (F), 
20% from protein (P), B — 40% from CH, 30% from F, 
and 30% from P. The calorie content was based on 
declared pre-study consumption (mean 1475 calories 
a day) and remained the same for the whole interven-
tion period. The CH content was repeated for each 
day of the study and for each meal for a diet A and 
a diet B, respectively. The total daily consumption of 
calories from fat and protein was also fixed; how-
ever, the fat/protein proportions for individual meals 
could have changed from day to day. The study was 
performed in home settings and all the meals were 
delivered to the patients. The subjects were allowed to 
drink water and other CH free drinks without restric-
tions. Each patient was exposed to the following diet 
pattern: diet A — 9 days, the wash-out — 7 days, diet 
B — 9 days (Fig. 1). At study entry, the memories of the 
patients’ own blood glucose meters were downloaded 
for further analysis. The patients were asked to per-
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form self-monitoring of blood glucose with their own 
blood glucose meters for the whole study period. The 
following daily pattern for taking blood glucose levels 
was recommended: fasting, 2 hours after breakfast, 
2 hours before and after lunch and 2 hours before and 
after dinner. Glucose patterns during days 4 to 9 when 
on diet A and diet B were assessed with the blinded 
continuous glucose monitoring (CGM) system (iPro2, 
Medtronic, USA). For the purpose of the study the Enlite 
Sensors (Medtronic) were used. All the patients submit-
ted informed consent. The study was approved by the 
Bioethical Committee of the Jagiellonian University.
Results
In comparison to pre-study glucose patterns, the 
implementation of diet A resulted in a decrease of mean 
glucose levels (glucometer data) from 187 to 153 mg/dL 
(p = 0.0001). Blood glucose variability as measured 
with standard deviation (SD) was reduced from 
84 mg/dL to 44 mg/dL. Switching from diet A to diet 
B resulted in a decrease of mean glucose levels (CGMS 
data) from 145 mg/dL to 133 mg/dL (p = 0.0001), 
SD reduction from 51 to 42 mg/dL (p = 0.0429), and 
a decrease of time spent above the target of 180 mg/dL 
from 18% to 11% (p = 0.0006). One of the patients’ 
Continuous Glucose Monitoring (CGM) records on 
a diet A and a diet B is shown in Figure 2. There were 
no episodes of severe hypoglycaemia. 
Discussion
The prandial insulin requirement is mostly driven by 
the meal CH amount and its quality. Treatment with PMHI 
implies fixed insulin doses as well as a steady proportion 
of both basal and prandial insulin components. Thus, 
for fixed prandial insulin, a repeatable, steady CH meal 
content also seems to be needed. This clinical experiment 
shows that such an approach helps to achieve satisfactory 
glycaemic control (as assessed here by a CGM system) in 
patients with T2DM on PMHI. There is a significant num-
ber of insulin treated T2DM patients for whom allowance 
for wide modifications of daily insulin doses may be not 
only difficult but also dangerous due to limited compli-
ance and co-operation abilities [10]. It seems that easy to 
understand diet modification may be easier for them to 
implement, repeatable and steady CH meal content may 
be a solution of choice for this group of patients. The 
need for consistent carbohydrate intake with respect to 
time and amount which can result in improved glycaemic 
control and reduced risk for hypoglycaemia in T2DM pa-
tients treated with pre-mixed insulins was recognized in 
the recommendations by American Diabetes Association 
(ADA) (evidence rating „B”) [11]. 
It has to be added that a moderate reduction in 
CH content produced further improvement in the pa-
tients’ glycaemic control. It has recently been shown 
that carbohydrate restriction according to baseline 
HbA1c levels may improve glycaemic control in T2DM 
patients [12]. Of interest, moderate reduction in car-
bohydrate content with time led also to the reduction 
of total energy intake [12]. It is important, however, to 
place greater emphasis on the role of various types of 
carbohydrate foods for glycaemic control, which was 
not a subject of investigation in present study [13]. 
Unfortunately there is no general agreement con-
cerning the ideal proportion of carbohydrates in diet 
recommended for patients with diabetes [1, 3, 5, 6]. 
The recommendations by ADA state that there is not an 
ideal percentage of calories from carbohydrate, protein, 
and fat for all people with diabetes; therefore, macro-
nutrient distribution should be based on individualized 
Figure 1. Schematic presentation of the study design. SMBG — self blood glucose monitoring; CGM — continuous  glucose 
monitoring
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assessment of current eating patterns, preferences, and 
metabolic goals [11].
Although this study was performed in an artificial 
environment of pre-prepared and ready to use meals, its 
results simply suggest that dietary education in T2DM 
patients treated with PMHI should include information 
on how to maintain a repeated amount of CH in their 
diet on a daily basis. Focusing on this aspect of dietary 
intervention may improve patients’ diet acceptance 
and compliance [14]. The individual content of other 
food components, such as fat and protein, seems to 
be of less importance as long as their total summarized 
proportion is fixed.
Conclusions
Consistent and repeatable CH with their moderate 
restriction along with steady calorie intake allow to 
improve glycaemic control in T2DM patients treated 
with PMHI as manifested by a significant reduction of 
mean glucose levels and decreased blood glucose vari-
ability. We postulate that in T2DM patients treated with 
PMHI an emphasis is put on education how to maintain 
a recommended pattern of CHs intake.
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